JP7282736B2 - カプサイシンを使用した疼痛の治療のための方法及び組成物 - Google Patents

カプサイシンを使用した疼痛の治療のための方法及び組成物 Download PDF

Info

Publication number
JP7282736B2
JP7282736B2 JP2020502343A JP2020502343A JP7282736B2 JP 7282736 B2 JP7282736 B2 JP 7282736B2 JP 2020502343 A JP2020502343 A JP 2020502343A JP 2020502343 A JP2020502343 A JP 2020502343A JP 7282736 B2 JP7282736 B2 JP 7282736B2
Authority
JP
Japan
Prior art keywords
joint
certain embodiments
patient
skin
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020502343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527574A (ja
JP2020527574A5 (enExample
Inventor
ジェイムズ・エヌ・キャンベル
ピーター・ディ・ハンソン
ゲイリー・エフ・ムッソ
ドレイゼン・オストビック
ランドール・スティーブンズ
Original Assignee
セントレクシオン セラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントレクシオン セラピューティクス コーポレイション filed Critical セントレクシオン セラピューティクス コーポレイション
Publication of JP2020527574A publication Critical patent/JP2020527574A/ja
Publication of JP2020527574A5 publication Critical patent/JP2020527574A5/ja
Priority to JP2023081213A priority Critical patent/JP7738031B2/ja
Application granted granted Critical
Publication of JP7282736B2 publication Critical patent/JP7282736B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/10—Cooling bags, e.g. ice-bags
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0001—Body part
    • A61F2007/0039—Leg or parts thereof
    • A61F2007/0042—Knee

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
JP2020502343A 2017-07-20 2018-07-20 カプサイシンを使用した疼痛の治療のための方法及び組成物 Active JP7282736B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023081213A JP7738031B2 (ja) 2017-07-20 2023-05-17 カプサイシンを使用した疼痛の治療のための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535003P 2017-07-20 2017-07-20
US62/535,003 2017-07-20
PCT/US2018/043094 WO2019018769A1 (en) 2017-07-20 2018-07-20 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023081213A Division JP7738031B2 (ja) 2017-07-20 2023-05-17 カプサイシンを使用した疼痛の治療のための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2020527574A JP2020527574A (ja) 2020-09-10
JP2020527574A5 JP2020527574A5 (enExample) 2021-08-26
JP7282736B2 true JP7282736B2 (ja) 2023-05-29

Family

ID=65016186

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020502343A Active JP7282736B2 (ja) 2017-07-20 2018-07-20 カプサイシンを使用した疼痛の治療のための方法及び組成物
JP2023081213A Active JP7738031B2 (ja) 2017-07-20 2023-05-17 カプサイシンを使用した疼痛の治療のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023081213A Active JP7738031B2 (ja) 2017-07-20 2023-05-17 カプサイシンを使用した疼痛の治療のための方法及び組成物

Country Status (11)

Country Link
US (4) US20200206166A1 (enExample)
EP (1) EP3654961B1 (enExample)
JP (2) JP7282736B2 (enExample)
CN (1) CN111201015A (enExample)
AU (1) AU2018302342B2 (enExample)
BR (1) BR112020000989A2 (enExample)
CA (1) CA3069540A1 (enExample)
ES (1) ES3018268T3 (enExample)
IL (1) IL272036B2 (enExample)
MX (1) MX2020000488A (enExample)
WO (1) WO2019018769A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023116457A (ja) * 2017-07-20 2023-08-22 セントレクシオン セラピューティクス コーポレイション カプサイシンを使用した疼痛の治療のための方法及び組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021534207A (ja) * 2018-08-24 2021-12-09 セントレクシオン セラピューティクス コーポレイション 膝関節痛の治療のためのカプサイシン連続投薬方法
CN114028540B (zh) * 2021-11-26 2023-10-17 海南鑫开源医药科技有限公司 一种具有镇痛作用的组合物、微针贴片及其制备方法以及应用
CN115006379B (zh) * 2021-12-28 2023-12-15 南京清普生物科技有限公司 一种trpv1激动剂原位膜剂组合物，及其制备方法和用途
JP2025534350A (ja) * 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536998A (ja) 2012-11-12 2015-12-24 エイピーアイ・ジェネシス，エルエルシー 水性カプサイシノイド配合物ならびにその製造法および使用法
JP2016540830A (ja) 2013-11-12 2016-12-28 ヴィズリ・ヘルス・サイエンスィズ・エルエルシー 水性カプサイシノイド配合物ならびに製造法および使用法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US5099030A (en) 1987-03-09 1992-03-24 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5431914A (en) 1992-04-17 1995-07-11 Adekunle; Michael Method of treating an internal condition by external application of capsaicin without the need for systemic absorption
US5985860A (en) 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
EP0646372B1 (de) 1993-09-30 1999-03-31 Medichemie Ag Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie
US5762963A (en) 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids
US6248788B1 (en) 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
WO1998020867A1 (en) 1996-11-15 1998-05-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists
US6060060A (en) 1997-01-31 2000-05-09 Bmb Patent Holding Corporation Analgesic compositions from sweet peppers and methods of use thereof
ATE219674T1 (de) 1997-03-13 2002-07-15 James N Campbell Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika
JP2002514221A (ja) 1997-05-27 2002-05-14 アルゴス ファーマシューティカル コーポレーション カプサイシノイド及びその強化薬を含有する鎮痛薬組成物
WO2002076444A1 (en) 2001-03-22 2002-10-03 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Molecular neurochirurgerie for pain control administering locally capsaicin or resiniferatoxin
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
US20030104085A1 (en) 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
CA2493041C (en) 2002-07-19 2011-08-16 Dominik Meyer Injectable pharmaceutical composition for treating post-operative joint pain comprising an amide local anesthetic
JP2006513267A (ja) 2002-12-18 2006-04-20 アルゴルクス ファーマスーティカルズ，インク カプサイシノイドの投与
US20040161481A1 (en) 2002-12-18 2004-08-19 Algorx Administration of capsaicinoids
EA012599B1 (ru) 2003-04-10 2009-10-30 Ньюроджескс, Инк. Способы и композиции для введения агонистов trpv1
EP2298287B1 (en) 2003-12-19 2018-04-11 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
MX2007006253A (es) 2004-11-24 2007-10-18 Anesiva Inc Formulacion de gel de capsaicinoide y usos para esta.
ES2355109T3 (es) 2004-12-22 2011-03-22 Mestex Ag Mezcla de un agonista de receptor de vainilloide con una sustancia inhibidora de la regeneración nerviosa, su utilización para la fabricación de un analgésico y procedimiento de aplicación de este fármaco.
WO2006069452A1 (de) 2004-12-28 2006-07-06 Mestex Ag Verwendung eines vanilloidrezeptoragonisten zusammen mit einem glycosaminoglycan oder proteoglycan für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
PL1838301T3 (pl) 2004-12-28 2015-08-31 Mestex Ag Użycie resiniferatotoksyny (RTX) dla wytwarzania środka leczącego stany bólowe
US20060222690A1 (en) * 2005-03-30 2006-10-05 Bley Keith R Low-concentration capsaicin patch and methods for treating neuropathic pain
US20080160487A1 (en) 2006-12-29 2008-07-03 Fairfield Language Technologies Modularized computer-aided language learning method and system
US8158682B2 (en) 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
CN101507818B (zh) 2008-12-15 2010-11-10 中国人民武装警察部队医学院 辣椒碱β-环糊精包合物及包合物的脂质体及凝胶
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20130303495A1 (en) 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
CA2795045C (en) * 2010-03-30 2022-07-05 Julia Cole Finkel Apparatus and method for human algometry
BR112014005358A8 (pt) * 2011-09-09 2017-10-03 Propella Therapeutics Inc Composições compreendendo agonista seletivo de trpv1 e seus usos
US9566187B2 (en) 2012-03-13 2017-02-14 Breg, Inc. Cold therapy systems and methods
ES2644935T3 (es) 2012-04-18 2017-12-01 Mallinckrodt Llc Composiciones farmacéuticas de liberación inmediata con propiedades disuasorias del abuso
WO2013158814A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate release, abuse deterrent pharmaceutical compositions
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
EP2879660A1 (de) 2012-08-03 2015-06-10 Mestex AG Resiniferatoxin-lösung
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
GB201317756D0 (en) 2013-10-08 2013-11-20 Critical Pharmaceuticals Ltd New process
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
EP3096740B1 (en) 2014-01-24 2020-09-30 Sentiss Pharma Private Limited Pharmaceutical composition comprising brinzolamide
EA201692060A1 (ru) 2014-04-14 2017-02-28 Флекс Фарма, Инк. Активаторы ионного канала и способы их применения
KR102073258B1 (ko) 2014-04-15 2020-02-04 비쭈리 헬스 사이언스 엘엘씨 통증 완화용 국소 조성물, 제조방법 및 용도
CN105030760B (zh) 2014-04-24 2018-10-02 长弘生物科技股份有限公司 稳定医药组合物
WO2015198350A1 (en) 2014-06-25 2015-12-30 Synergia Bio Sciences Private Limited A pharmaceutical oil-in-water nano-emulsion
EA033046B1 (ru) 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
AU2015306063A1 (en) 2014-08-19 2017-04-13 Mandishora Israel MUZARI Capsaicinoids and uses thereof as medicaments
US20180311189A1 (en) 2014-11-13 2018-11-01 Centrexion Therapeutics Corporation Capsaicinoids for Use in Treating ACRAL Lick Granuloma
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
HK1253050A1 (zh) 2015-02-02 2019-06-06 英仕柏集团有限责任公司 稳定的富马酸二烷基酯组合物
MX2017015322A (es) 2015-05-29 2018-03-28 Sun Pharmaceutical Ind Ltd Composicion farmaceutica oral de isotretinoin.
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
WO2017087803A1 (en) 2015-11-20 2017-05-26 Sorrento Therapeutics, Inc. Methods for pain treatment using resiniferatoxin
AU2017210315A1 (en) * 2016-01-22 2018-08-16 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of morton's neuroma pain
WO2017147146A1 (en) 2016-02-23 2017-08-31 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
WO2017205534A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
JP7100635B2 (ja) * 2016-11-02 2022-07-13 セントレクシオン セラピューティクス コーポレイション 安定な水性カプサイシン注射製剤およびその医学的使用
WO2018217937A1 (en) 2017-05-24 2018-11-29 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
IL272036B2 (en) 2017-07-20 2025-01-01 Centrexion Therapeutics Corp Methods and compositions for treating pain using capsaicin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536998A (ja) 2012-11-12 2015-12-24 エイピーアイ・ジェネシス，エルエルシー 水性カプサイシノイド配合物ならびにその製造法および使用法
JP2016540830A (ja) 2013-11-12 2016-12-28 ヴィズリ・ヘルス・サイエンスィズ・エルエルシー 水性カプサイシノイド配合物ならびに製造法および使用法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Neurophysiology，1991年， 66(1)，pp.190-211

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023116457A (ja) * 2017-07-20 2023-08-22 セントレクシオン セラピューティクス コーポレイション カプサイシンを使用した疼痛の治療のための方法及び組成物
JP7738031B2 (ja) 2017-07-20 2025-09-11 セントレクシオン セラピューティクス コーポレイション カプサイシンを使用した疼痛の治療のための方法及び組成物

Also Published As

Publication number Publication date
US20210299072A1 (en) 2021-09-30
JP2020527574A (ja) 2020-09-10
US20200360314A1 (en) 2020-11-19
MX2020000488A (es) 2020-10-28
ES3018268T3 (en) 2025-05-14
BR112020000989A2 (pt) 2020-07-14
AU2018302342A1 (en) 2020-02-06
IL272036B1 (en) 2024-09-01
JP2023116457A (ja) 2023-08-22
US20250312298A1 (en) 2025-10-09
WO2019018769A1 (en) 2019-01-24
CN111201015A (zh) 2020-05-26
EP3654961A1 (en) 2020-05-27
AU2018302342B2 (en) 2024-08-08
US12201594B2 (en) 2025-01-21
JP7738031B2 (ja) 2025-09-11
EP3654961A4 (en) 2021-04-21
US11026903B2 (en) 2021-06-08
EP3654961C0 (en) 2025-01-08
IL272036A (en) 2020-03-31
CA3069540A1 (en) 2019-01-24
US20200206166A1 (en) 2020-07-02
IL272036B2 (en) 2025-01-01
EP3654961B1 (en) 2025-01-08

Similar Documents

Publication Publication Date Title
JP7738031B2 (ja) カプサイシンを使用した疼痛の治療のための方法及び組成物
CN104968330A (zh) 用于治疗剧痛的组合物及方法
Daneshkazemi et al. The efficacy of eutectic mixture of local anesthetics as a topical anesthetic agent used for dental procedures: A brief review
US20140142073A1 (en) Aqueous based capsaicinoid formulations and methods of manufacture and use
KR102657458B1 (ko) 안정한 수성의 캡사이신 주사 가능한 제형 및 이의 의학적 용도
US20200297670A1 (en) Capsaicin Sequential Dosing Method for Treatment of Morton's Neuroma Pain
US20250241879A1 (en) Capsaicin sequential dosing method for treatment of knee joint pain
Webster et al. Review of intra‐articular local anaesthetic administration in horses: Clinical indications, cytotoxicity, and outcomes
Wong et al. Comparison of the Effect of Two Different Doses of 0.75% Glucose‐Free Ropivacaine for Spinal Anesthesia for Lower Limb and Lower Abdominal Surgery
US20100190860A1 (en) Methods for selectively enhancing antinociceptive potency of local anesthetics
HK40031064B (en) Compositions and their use for treatment of pain using capsaicin
HK40031064A (en) Compositions and their use for treatment of pain using capsaicin
Mosimann et al. Usefulness of intra-articular bupivacain and lidocain adjunction in MR or CT arthrography: A prospective study in 148 patients
Ali et al. Comparison of analgesic effect of ketorolac and lidocaine in reduction of propofol induced pain
Mallika et al. ROLE OF DEXMEDETOMIDINE AND CLONIDINE AS ADJUVANTS WITH ROPIVACAINE IN EPIDURAL ANAESTHESIA-A COMPARATIVE STUDY
Shehab et al. Therapeutic efficacy of a preoperative epidural single shot of dexamethasone/levobupivacaine for postoperative analgesia (a placebo-controlled comparative study against epidural neostigmine/levobupivacaine)
Gritsenko et al. Postoperative Blocks That Afford Long-Lasting Pain Relief
Standard et al. PRESCRIBING INFORMATION

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230418

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230517

R150 Certificate of patent or registration of utility model

Ref document number: 7282736

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150